KR100345505B1 - Hollow fiber membrane and its manufacturing method - Google Patents
Hollow fiber membrane and its manufacturing method Download PDFInfo
- Publication number
- KR100345505B1 KR100345505B1 KR1019950041936A KR19950041936A KR100345505B1 KR 100345505 B1 KR100345505 B1 KR 100345505B1 KR 1019950041936 A KR1019950041936 A KR 1019950041936A KR 19950041936 A KR19950041936 A KR 19950041936A KR 100345505 B1 KR100345505 B1 KR 100345505B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- hollow fiber
- group
- spinning solution
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 46
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 229920002492 poly(sulfone) Polymers 0.000 claims abstract description 25
- 238000009987 spinning Methods 0.000 claims abstract description 21
- 229920000642 polymer Polymers 0.000 claims abstract description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002798 polar solvent Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 4
- 150000001340 alkali metals Chemical group 0.000 claims abstract description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000000701 coagulant Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 12
- 230000002785 anti-thrombosis Effects 0.000 abstract description 4
- 238000000502 dialysis Methods 0.000 abstract description 4
- 125000003636 chemical group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229940093476 ethylene glycol Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 229920001477 hydrophilic polymer Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000002965 anti-thrombogenic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical group CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920001464 poly(sodium 4-styrenesulfonate) Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0016—Coagulation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
- B01D69/087—Details relating to the spinning process
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/12—Specific ratios of components used
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/15—Use of additives
- B01D2323/218—Additive materials
- B01D2323/2182—Organic additives
- B01D2323/21839—Polymeric additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/219—Specific solvent system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/36—Hydrophilic membranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Vascular Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- External Artificial Organs (AREA)
Abstract
Description
[산업상 이용분야][Industrial use]
본 발명은 중공사막과 그 제조방법에 관한 것으로서, 더욱 상세하게는 인공투석막 등에 사용되는 폴리설폰(polysulfone)류 중공사막과 그 제조방법에 관한 것이다.The present invention relates to a hollow fiber membrane and a method for manufacturing the same, and more particularly, to a polysulfone-like hollow fiber membrane used in an artificial dialysis membrane and a method of manufacturing the same.
[종래 기술][Prior art]
양호한 기계적 성질과 높은 내열성 등을 가진 폴리설폰은 우수한 물리적 특성 때문에 각 분야에 있어서 많은 응용이 전개되고 있고 특히 중공사막(hollow fiber membrane)의 제조에도 많이 이용되고 있다. 하지만 폴리설폰 재질 자체의 소수성이 매우 크기 때문에 막을 제조한 이후 투과 효율이 기타 다른 재료에 비해 떨어지는 단점이 있고 인공신장 등 혈액과 접촉하는 분야에 응용될 때에는 혈액 응고 등의 문제를 일으킬 우려가 있다. 따라서 적당한 방법으로 폴리설폰막(membrane)을 개질하여 막의 물성을 유지하면서도 높은 투과 특성을 갖도록 하는 방법이 개발될 필요가 있으며, 또한 혈액과 접촉하는 응용 분야에 있어서는 항혈전성을 향상시키는 방법도 개발되어야 한다.Polysulfones having good mechanical properties and high heat resistance have many applications in each field because of their excellent physical properties, and are particularly used for the production of hollow fiber membranes. However, since the hydrophobicity of the polysulfone material itself is very high, the permeation efficiency is inferior to other materials after the membrane is manufactured, and when applied to an area in contact with blood, such as artificial kidneys, there is a possibility of causing problems such as blood coagulation. Therefore, a method of modifying a polysulfone membrane (membrane) by a suitable method to maintain a high permeability while maintaining the properties of the membrane need to be developed, and also to improve the antithrombogenic properties in the application area in contact with blood Should be.
폴리설폰의 친수화 및 방사성의 향상을 위해 폴리비닐피롤리돈 (polyvinylpyrolidone)이나 폴리에틸렌글리콜(polyethyleneglycol) 등의 친수성 고분자를 첨가하여 방사하는 방법은(Journal of Applied Polymer Science, Vol. 20, 2377-2394) 방사후 잔존 친수성 고분자의 양이 많지 않아서 효과가 크지 않고 오히려 잔존 친수성 고분자가 수질의 오염 문제를 일으킬 수 있는 문제점이 있다.In order to improve the hydrophilicity and radioactivity of polysulfone, a method of spinning by adding hydrophilic polymers such as polyvinylpyrolidone or polyethyleneglycol (Journal of Applied Polymer Science, Vol. 20, 2377-2394 ) Since the amount of hydrophilic polymer remaining after spinning is not large, the effect is not great. Rather, there is a problem that the remaining hydrophilic polymer may cause water pollution.
친수성 고분자를 가교제를 사용하여 고정화하는 방법이 일본 특개소 58-104940호에, 친수성 고분자를 열로 처리하거나 방사선으로 처리하여 가교 고정시키는 방법이 일본 특개소 63-97205호, 특개소 63-97634호에 기술되어 있다. 그러나, 상기한 방법들은 조작이 복잡하거나, 고가의 장비가 필요한 단점이 있다.The method of immobilizing a hydrophilic polymer using a crosslinking agent is described in Japanese Patent Application Laid-Open No. 58-104940, and the method of crosslinking and fixing a hydrophilic polymer by heat or radiation treatment is disclosed in Japanese Patent Application Laid-Open Nos. Described. However, the above methods are disadvantageous in that the operation is complicated or expensive equipment is required.
또한, 폴리설폰 재질 중공사막(hollow fiber membrane)의 항응고성을 실질적으로 향상시키는 방법에 대한 개발은 아직 미진한 실정이다.In addition, the development of a method for substantially improving the anticoagulation of the polysulfone hollow fiber membrane (hollow fiber membrane) is still insufficient.
[발명이 해결하려는 과제][Problems to Solve Invention]
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위한 것으로서, 본 발명의 목적은 폴리설폰막(polysulfone membrane)의 친수성 향상을 위한 투과 효율을 증대시킬 수 있고, 폴리설폰막의 항혈전성을 증대시킬 수 있는 중공사막과 그 제조방법에 관한 것이다.The present invention is to solve the problems of the prior art as described above, an object of the present invention can increase the transmission efficiency for improving the hydrophilicity of the polysulfone membrane (polysulfone membrane), and increase the antithrombogenic properties of the polysulfone membrane It relates to a hollow fiber membrane and a method of manufacturing the same.
[과제를 해결하기 위한 수단][Means for solving the problem]
상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 극성 용매 30~80중량부; 상기 극성 용매에 용해한 폴리설폰계 폴리머 20~40중량부를 포함하는 폴리설폰계 중공사막 제조용 방사용액에 있어서, 하기 일반식(Ⅰ)으로 나타내는 친수성비닐계 폴리머 1~50중량부를 포함하는 것을 특징으로 하는 폴리설폰계 중공사막 제조용 방사 용액과 폴리설폰계 수지를 해(海)성분으로 하고, 하기 일반식(Ⅰ)의 친수성 비닐계 폴리머를 도(島)성분으로 포함하는 폴리설폰계 중공사막을 제공한다.In order to achieve the object of the present invention as described above, the present invention is 30 to 80 parts by weight of a polar solvent; In the spinning solution for producing a polysulfone hollow fiber membrane containing 20 to 40 parts by weight of the polysulfone polymer dissolved in the polar solvent, 1 to 50 parts by weight of a hydrophilic vinyl polymer represented by the following general formula (I) Provided is a polysulfone hollow fiber membrane comprising a spinning solution for producing a polysulfone hollow fiber membrane and a polysulfone resin as a sea component, and containing a hydrophilic vinyl polymer of general formula (I) as an island component. .
(상기 식에서(In the above formula
로 이루어지는 그룹에서 선택된 것으로서, R1~R5중 최소한 하나는Selected from the group consisting of at least one of R 1 ~ R 5
로 이루어진 그룹에서 선택된 것이고, M은 알칼리 금속이며, R은 탄소수 1~5개인 알킬기이고, 또한 n은 1 이상의 정수이다)It is selected from the group consisting of, M is an alkali metal, R is an alkyl group having 1 to 5 carbon atoms, and n is an integer of 1 or more)
또한, 상기 중공사막의 인공 투석막으로서의 용도와 상기 중공사막을 분리막으로 사용하는 모듈 및 이 모듈의 인공 투석기로서의 용도 및 폴리설폰계 폴리머와 응고성 용매를 극성용매에 용해하여 고분자 방사 용액을 제조하고; 상기 방사용액을 이중 관형 구금을 통해 응고액조로 방사하여 중공사를 제조한 후; 상기 중공사를 수세 건조하여 막을 제조하는 공정을 포함하는 중공사막의 제조방법에 있어서, 상기 극성용매에 상기 일반식(Ⅰ)의 친수성 비닐(vinyl)계 폴리머를 용해하는 공정을 더 포함하는 것을 특징으로 하는 중공사막의 제조방법을 제공한다.In addition, a polymer spinning solution is prepared by dissolving the use of the hollow fiber membrane as an artificial dialysis membrane, the module using the hollow fiber membrane as a separator, the use of the module as an artificial dialysis machine, and a polysulfone polymer and a coagulating solvent in a polar solvent; Spinning the spinning solution into a coagulation bath through a double tubular detention to produce hollow fiber; A method for producing a hollow fiber membrane, comprising the step of washing the hollow fiber with water to dry the membrane, the method comprising: dissolving a hydrophilic vinyl polymer of the general formula (I) in the polar solvent. It provides a method for producing a hollow fiber membrane.
상기한 본 발명에 있어서, 상기 친수성 비닐계 폴리머를 1~20중량부의 양으로 포함하는 방사용액을 사용하는 것이 바람직하다. 상기 폴리머의 함량이 1중량부보다 작으면 친수화 효과가 없고 20중량부보다 많으면 원액의 안정성이 떨어져 방사성이 좋지 않게 되어 바람직하지 않다.In the present invention described above, it is preferable to use a spinning solution containing the hydrophilic vinyl polymer in an amount of 1 to 20 parts by weight. If the content of the polymer is less than 1 part by weight, there is no hydrophilic effect. If the content of the polymer is more than 20 parts by weight, the stability of the stock solution is poor and the radioactivity is not good.
상기한 본 발명에 있어서, 상기 극성 용매는 N,N-디메틸포름아마이드(N,N-dimethylformamide), N-메틸-2-피롤리돈(N-methyl-2-pyrrolidone) 등의 아마이드(amide)계 용매, 디메틸설폭사이드(dimethylsulfoxide)를 포함하는 그룹에서 선택되는 것인 바람직하다.In the present invention described above, the polar solvent is N, N-dimethylformamide (N, N-dimethylformamide), N-methyl-2-pyrrolidone (N-methyl-2-pyrrolidone) such as amide (amide) It is preferred that the solvent selected from the group containing a solvent, dimethylsulfoxide (dimethylsulfoxide).
상기한 본 발명에 있어서 물, 에틸렌 글리콜(ethylene glycol), 프로필 글리콜(propyl glycol)등의 다가알콜류 및 폴리에틸렌 글리콜(polyethylene glycol)로 이루어진 그룹에서 선택되는 것인 응고성 용매 30~80중량%를 더 포함한다.In the present invention, 30 to 80% by weight of a coagulant solvent, which is selected from the group consisting of polyhydric alcohols such as water, ethylene glycol, propyl glycol, and polyethylene glycol, is further included. Include.
상기한 본 발명에 있어서, 상기 폴리설폰은 10~30중량부의 양으로 사용하고, 상기 용매는 30~80중량부의 양으로 사용하는 것이 바람직하다.In the present invention described above, the polysulfone is preferably used in an amount of 10 to 30 parts by weight, and the solvent is preferably used in an amount of 30 to 80 parts by weight.
[발명의 구성 및 작용][Configuration and Function of Invention]
본 발명에서는 폴리설폰(이하 PSF)계 막(mebrane)의 친수성을 향상시키기 위해 하기식에 나타낸 바와 같은 폴리머(polymer)를 막(membrane)을 제조하기 위한고분자 방사 용액(dope) 조성에 첨가한다.In the present invention, in order to improve the hydrophilicity of the polysulfone (hereinafter PSF) -based membrane, a polymer as shown in the following formula is added to the polymer spinning solution (dope) composition for preparing the membrane.
(싱기 식에서(In the season)
로 이루어지는 그룹에서 선택된 것으로서, R1~R5중 최소한 하나는Selected from the group consisting of at least one of R 1 ~ R 5
로 이루어진 그룹에서 선택된 것이고, M은 알칼리 금속이며, R은 탄소수 1~5개인 알킬기이고, 또한 n은 1 이상의 정수이다)It is selected from the group consisting of, M is an alkali metal, R is an alkyl group having 1 to 5 carbon atoms, and n is an integer of 1 or more)
상기 식에서In the above formula
* R1, R2, R4, R5이 H 이고, R3가일 때를 PSS(polysulfate sodium salt)라 한다.R 1 , R 2 , R 4 and R 5 are H and R 3 is When is called polysulfate sodium salt (PSS).
본 발명에서 폴리설폰계 고분자는 하기 식(1), (2)에 나타낸 화합물로 구성된 고분자 물질을 말한다.In the present invention, the polysulfone polymer refers to a polymer material composed of the compounds represented by the following formulas (1) and (2).
상기 식과 같은 폴리머를 이용하면 종래 PSF 막의 친수화 처리 방법과 비교할 때 다음과 같은 유리한 점이 있다.The use of a polymer such as the above formula has the following advantages compared to the conventional hydrophilic treatment of PSF membranes.
(1) 상기 식과 같은 폴리머가 PSF와의 상호 작용이 크므로 막 제조후 막에 잔존할 수 있는 친수성 폴리머의 양이 극대화 되며 이에 따라 친수화 효과가 매우 크다. : 종래 PSF의 친수화 효과를 높이기 위해 사용된 폴리비닐피롤리돈(polyvinylpyrrolidone (이하 PVP)) 등은 친수화 효과는 우수하지만 PSF와의 상호 작용이 거의 없고 분자와 분자 사이에 작용하는 기본적인 힘만이 작용한다. 따라서 막제조 후 잔존되는 PVP는 막의 세정시 쉽게 씻겨 나가거나 실제 막을 사용할 때에 떨어져나가 오염원으로 작용할 가능성이 높다. 이러한 이유로 인공신장 등 고도의 청정성이 유지되어야 하는 응용 분야에 있어서는 주의를 요하며 PSF 주쇄에 PVP 등을 화학적 결합을 이루게 하는 방법 들이 개발되고 있는 형편이다.(1) Since the polymer as described above has a large interaction with PSF, the amount of hydrophilic polymer remaining in the membrane after membrane preparation is maximized, and thus the hydrophilization effect is very high. : Polyvinylpyrrolidone (PVP), which is used to enhance the hydrophilic effect of PSF, has excellent hydrophilic effect but little interaction with PSF and only basic force acting between molecules. do. Therefore, the remaining PVP after membrane formation is likely to be easily washed off when the membrane is washed or to fall off and act as a pollution source when the membrane is actually used. For this reason, caution is required in applications where high cleanliness, such as artificial kidneys, should be maintained, and methods for chemically bonding PVP to the PSF backbone are being developed.
본 발명은 이러한 단점을 해결하고자 PSF와 물리적 결합력이 우수하면서도친수화 효과가 좋은 예컨데 폴리(소디움 4-스티렌설포네이트)(poly(sodium 4-styrenesulfonate)(이하 PSS))를 이용하였다. 이렇게 PSS와 PSF의 물리적 상호 작용이 큰 이유를 아래 그림에 나타내었다.In order to solve this drawback, the present invention used poly (sodium 4-styrenesulfonate) (hereinafter referred to as PSS) having good physical bonding strength and good hydrophilic effect. The reason why the physical interaction between PSS and PSF is great is shown in the figure below.
상기한 앞 그림에 나타낸 바와 같이 PSF 사슬 내에는 전자공여기(electron donating group)인 페녹시(phenoxy)기와 알킬기가 양쪽에 있어서 전자를 공여함으로써 풍부한 전자 밀도를 가지고 있는 페닐링이 있으며, PSS에는 강력한 전자흡인기(electron withdrawing group)인 설폰(sulfone)기가 전자를 잡아당김으로 말미암아 전자밀도가 상대적으로 작아진 페닐 링이 존재한다. 이렇게 전자 밀도가 차이가있는 두 개의 페닐링 사이에늘 이른바 전하 이동 상호 작용(charge transfer interaction)이라는 인력이 생기며, 이러한 힘을 이용하여 두 물질 사이의 강한 접착력을 유도할 수 있다. 방사선 처리나 특수한 약제를 사용하여 PSF와 화학결합을 유도하는 식의 종래 방법에서 탈피하여 단순히 강한 물리적 결합 만으로 친수성 고분자 물질을 PSF 막(membrane) 내에 잔존시킬 수 있는 힘을 발견하고 그것을 응용하였다는 데에 본 발명의 우수성이 있다고 하겠다.As shown in the preceding figure, there is a phenyl ring in the PSF chain which has abundant electron density by donating electrons on both sides of the phenoxy group and the alkyl group, which are electron donating groups. There is a phenyl ring whose electron density is relatively small due to the electron withdrawing group sulfone group attracting electrons. The attraction between the two phenyl rings with different electron density is called a charge transfer interaction, and this force can be used to induce strong adhesion between the two materials. It was found to be able to escape from the conventional method of inducing chemical bonds with PSF using radiation treatment or special agent, and to find and apply the force that can remain hydrophilic polymer material in PSF membrane by simply strong physical bonding. It will be said that the superiority of the present invention.
(2) PSF 막(membrane)의 항혈전성 향상(2) improvement of antithrombogenicity of PSF membrane
현재 인공신장과 같이 피와 접촉하는 응용 분야에 있어서 막(membrane)의 항혈전성은 매우 중요하지만 헤파린과 같이 혈전 생성을 막는 물질과 함께 사용하는 방법 이외에 마땅한 방법이 없는 실정이다. 그러나 헤파린의 과다 사용은 인체에 여러 가지 부작용이 발생될 우려가 있으므로 그 사용량은 극히 제한되어야 한다. 따라서 헤파린의 사용 극소화 시켜도 혈전 생성이 일어나지 않는 막의 표면이 음전하를 띠게하는 방법이 알려져 있으며, 본 발명에서 개발한 막중 특히 PSS가 첨가된 막은 설포네이트(sulfonate)기 때문에 음전하를 띠고 있으므로 우수한 항혈전성을 보유하게 된다. 또한 설포네이트(sulfonate)기의 항혈전 효과는 단순히 음전하를 띠고 있다는 사실이외에도 직접적으로 혈전 생성을 방해하는 작용이 있으며, 이러한 사실은 현재 항혈전제로 가장 흔하게 이용되는 헤파린의 분자 구조가 아래 그림과 같이 셀룰로즈(cellulose)의 몇 개의 OH기가 -SOOH 기로 치환되어 있다는 것을통해 이해될 수 있다.At present, the antithrombogenicity of membranes is very important in blood-contacting applications such as artificial kidneys, but there is no proper method other than the use with materials that prevent blood clots, such as heparin. However, the excessive use of heparin may cause various side effects in the human body, so its amount should be extremely limited. Therefore, the method of making the surface of the membrane which does not generate a thrombus even if the use of heparin is minimized is known. Among the membranes developed in the present invention, especially the PSS-added membrane has a negative charge because it is a sulfonate, so it has excellent antithrombogenicity Will hold. In addition to the fact that the anti-thrombotic effect of the sulfonate group is not only negatively charged, it also directly interferes with the formation of blood clots. This fact indicates that the molecular structure of heparin, the most commonly used anti-thrombotic agent, is shown in the figure below. It can be understood through the fact that several OH groups in cellulose are substituted with -SOOH groups.
이하 본 발명의 바람직한 실시예 및 비교예를 기재한다. 그러나 하기한 실시예 및 비교에는 본 발명의 이해를 돕기 위한 본 발명의 바람직한 일실시예일뿐 본 발명이 하기한 실시예에 한정되는 것은 아니다.Hereinafter, preferred examples and comparative examples of the present invention are described. However, the following examples and comparisons are only preferred embodiments of the present invention to aid in understanding the present invention, and the present invention is not limited to the following examples.
실시예 1Example 1
폴리설폰(p-3500: 아모코(AMOCO)사 제품) 17wt%와 PSS 9wt%, PEG 10wt%를 64wt%의 DMF에 교반 용해하여 투명한 방사 원액을 제조하였다. 이 방사원액을 외경 0.35 mm, 내경 0.2 mm, 주입구멍지름 0.15 mm의 환상슬릿 구금으로부터 2.0 g/min의 비율로 토출하고 동시에 주입 구멍으로부터 내부응고액인 물을 1.3 g/min의 속도로 주입했다. 이후 10 cm의 에어갭을 거치게 하고 25℃의 응고욕(물)으로 중공사를 안내하여 응고 수세한 후 33 m/min의 권취속도로 실패형상으로 권취하였다. 얻어진 중공사의 UFR은 250ml/min/mmHg/m2이었고 항혈전성은 양호하였다.17 wt% of polysulfone (p-3500: AMOCO Co., Ltd.), 9 wt% of PSS, and 10 wt% of PEG were stirred and dissolved in 64 wt% of DMF to prepare a transparent spinning stock solution. This spinning stock solution was discharged at a rate of 2.0 g / min from an annular slit mold having an outer diameter of 0.35 mm, an inner diameter of 0.2 mm, and an injection hole diameter of 0.15 mm, and at the same time, water as an internal coagulating solution was injected from the injection hole at a rate of 1.3 g / min. . After 10 cm through the air gap, the hollow fiber was guided to a coagulation bath (water) at 25 ℃ washed by coagulation and wound in a failure shape at a winding speed of 33 m / min. The obtained UFR of the hollow fiber was 250 ml / min / mmHg / m 2 and the antithrombogenic property was good.
실시예 2~5Examples 2-5
위 실시예 1과 실질적으로 동일한 방법으로 PSS 첨가량만 아래 표1과 같이 바꾸어 중공사를 제조하였다.In the same manner as in Example 1 above, only PSS addition amount was changed as shown in Table 1 below to prepare a hollow fiber.
비교예 1~3Comparative Examples 1 to 3
위 실시예 1과 동일하며 PSS대신 PVP를 사용하거나, 또는 고분자를 첨가하지 않고 중공사를 제조하였다.Same as Example 1 above, using hollow fiber PVS instead of PSS, or without adding a polymer was prepared hollow fiber.
상기한 실시예 2~5 및 비교예 1~3에서 얻어진 중공사막 각각의 투과성능(UFR)과 항혈전성을 다음과 같이 측정하여 그 결과률 하기의 표 1에 나타내었다.Permeability (UFR) and antithrombotic properties of each of the hollow fiber membranes obtained in Examples 2 to 5 and Comparative Examples 1 to 3 were measured as follows, and the results are shown in Table 1 below.
(1) 투과성능 평가 (UFR)(1) Transmission Performance Evaluation (UFR)
길이 15 cm의 중공사 20 가닥을 사용하여 소형 유리관 모듈을 작성하여 막간 압력을 약 100 mmHg로 유지시킨 상태에서의 물의 투과성을 산출하였다.(UFR: ml/min/mmHg/m2)A small glass tube module was prepared using 20 strands of hollow fiber of 15 cm in length to calculate the water permeability while maintaining the intermembrane pressure at about 100 mmHg. (UFR: ml / min / mmHg / m 2 )
(2) 항혈전성 평가(2) antithrombotic evaluation
중공사를 혈액과 1시간 동안 접촉시킨 후 2.0 wt% 글루타르알데하이드(glutaraldehyde)를 함유한 식염 수용액에 처리하여 점착성분을 고정시키고 인산완충액(pH 7.4)으로 세정후 표면에 점착된 성분을 SEM으로 관찰하였다. 이때 100 nm2내에 점착된 혈소판의 개수가 10개 미만일 때는 양호, 10~100개일 때는 보통, 100개 이상일 때는 불량으로 표시하였다.The hollow fiber was contacted with blood for 1 hour, and then treated with an aqueous salt solution containing 2.0 wt% glutaraldehyde to fix the adhesive component. Observed. At this time, the number of platelets adhered in 100 nm 2 is good when less than 10, usually 10 to 100, it was marked as bad when more than 100.
본 발명에 따라 제조된 중공사막이 종래의 중공사막에 비해 UFR과 항혈전성이 우수하게 나타났다.The hollow fiber membrane prepared according to the present invention showed better UFR and antithrombogenicity than the conventional hollow fiber membrane.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950041936A KR100345505B1 (en) | 1995-11-17 | 1995-11-17 | Hollow fiber membrane and its manufacturing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950041936A KR100345505B1 (en) | 1995-11-17 | 1995-11-17 | Hollow fiber membrane and its manufacturing method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970025684A KR970025684A (en) | 1997-06-24 |
KR100345505B1 true KR100345505B1 (en) | 2002-10-31 |
Family
ID=37488578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950041936A Expired - Fee Related KR100345505B1 (en) | 1995-11-17 | 1995-11-17 | Hollow fiber membrane and its manufacturing method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100345505B1 (en) |
-
1995
- 1995-11-17 KR KR1019950041936A patent/KR100345505B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR970025684A (en) | 1997-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0193725B1 (en) | Process for spinning hollow fiber membranes | |
US4530703A (en) | Cross-linked polyarylene oxide membranes | |
JP2008543546A (en) | Cross-linking treatment of polymer film | |
CN101084057B (en) | Membrane post-processing method | |
US4851121A (en) | Process for rendering porous membrane hydrophilic | |
US5879554A (en) | Polysulfone membrane and method for its manufacture | |
KR100424995B1 (en) | Selective permeable membrane and manufacturing method thereof | |
CN105013355A (en) | Heparan polyethersulfone hollow fiber membrane and preparation method and applications thereof | |
JP3640737B2 (en) | Polysulfone-based permselective hollow fiber membrane | |
JP3714686B2 (en) | Polysulfone-based hollow fiber membrane and method for producing the same | |
KR100345505B1 (en) | Hollow fiber membrane and its manufacturing method | |
WO2000072950A1 (en) | Cellulose derivative hollow fiber membrane | |
KR100434564B1 (en) | A polysulfone-based hollow fiber membrane with excellent durability for steam, and a process of preparing for the same | |
JP2000135421A (en) | Polysulfone-base blood purifying membrane | |
JP3895060B2 (en) | Polysulfone blood treatment membrane | |
JPS62269704A (en) | Surface hydrophilic highly selective permeable membrane and its manufacturing method | |
KR100434565B1 (en) | A polysulfone-based hollow fiber membrane with excellent durability for steam, and a process of preparing for the same | |
JP2803142B2 (en) | Method for producing polysulfone hollow fiber membrane | |
JP4386607B2 (en) | Polysulfone blood purification membrane production method and polysulfone blood purification membrane | |
KR100231262B1 (en) | The process for producing hollow fiber membrane having an improved rewettability | |
Elsen et al. | Advantages of meltspun membrane technology compared to solution spinning | |
JPH0470936B2 (en) | ||
KR100416134B1 (en) | A polysulfone based hollow fiber membranes with high strength and performance, and a process of preparing for the same | |
AU2005312347A1 (en) | Membrane post treatment | |
JPH08141377A (en) | Porous separation membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19951117 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19991111 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19951117 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20011031 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20020627 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20020710 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20020711 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20050614 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20050614 Start annual number: 4 End annual number: 4 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20070609 |